These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9061853)

  • 41. Food and Drug Administration; statement of organization, functions, and delegations of authority: Center for Food Safety and Applied Nutrition (CFSAN)--HHS.
    Fed Regist; 1992 Nov; 57(222):54239-41. PubMed ID: 10122661
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk assessment of carcinogens in food.
    Barlow S; Schlatter J
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):180-90. PubMed ID: 19909764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. US FDA "Redbook II" immunotoxicity testing guidelines and research in immunotoxicity evaluations of food chemicals and new food proteins.
    Hinton DM
    Toxicol Pathol; 2000; 28(3):467-78. PubMed ID: 10862567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory forum opinion piece: Tox21 and toxicologic pathology.
    Bucher JR
    Toxicol Pathol; 2013 Jan; 41(1):125-7. PubMed ID: 22692375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of 'secondary mechanism' in the regulation of carcinogens; a chronology.
    Scheuplein RJ
    Cancer Lett; 1995 Jun; 93(1):103-12. PubMed ID: 7600537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA's priority-based assessment of food additives. III. Specific toxicity parameters.
    Hattan DG; Rulis AM
    Regul Toxicol Pharmacol; 1986 Jun; 6(2):181-91. PubMed ID: 3726179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Food and Drug Administration Information Center on adverse reactions and hazards.
    Saiger GL
    Pharmakotherapia; 1965; 2(2):124-8. PubMed ID: 5875220
    [No Abstract]   [Full Text] [Related]  

  • 49. The danger in food safety policies.
    Hall RH
    Can Med Assoc J; 1978 Jan; 118(1):83-7. PubMed ID: 620390
    [No Abstract]   [Full Text] [Related]  

  • 50. What will food science require of toxicology?
    Hall RL
    Fundam Appl Toxicol; 1984 Jun; 4(3 Pt 2):S278-83. PubMed ID: 6745546
    [No Abstract]   [Full Text] [Related]  

  • 51. Safety of carrageenan used in foods.
    Sarett HP
    Lancet; 1981 Jan; 1(8212):151-2. PubMed ID: 6109821
    [No Abstract]   [Full Text] [Related]  

  • 52. [Toxicology in development and its relationship to pharmacology].
    van Genderen H
    Tijdschr Diergeneeskd; 1990 Jul; 115(14):689-94. PubMed ID: 2197764
    [No Abstract]   [Full Text] [Related]  

  • 53. Health update on sulfites in food and drugs.
    Oberste DM
    J Ark Med Soc; 1984 Jul; 81(2):130-2. PubMed ID: 6236206
    [No Abstract]   [Full Text] [Related]  

  • 54. Under the conditions of intended use - New developments in the FEMA GRAS program and the safety assessment of flavor ingredients.
    Hallagan JB; Hall RL
    Food Chem Toxicol; 2009 Feb; 47(2):267-78. PubMed ID: 19041920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Digital pathology and federalism.
    Allen TC
    Arch Pathol Lab Med; 2014 Feb; 138(2):162-5. PubMed ID: 23738763
    [No Abstract]   [Full Text] [Related]  

  • 56. Irradiation in the production, processing and handling of food. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Nov; 77(231):71316-20. PubMed ID: 23227569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical toxicology and drug regulation: a United Kingdom perspective.
    Waring WS; McGettigan P
    Clin Toxicol (Phila); 2011 Jul; 49(6):452-6. PubMed ID: 21824056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA perspectives on the use of teratology data for human risk assessment.
    Frankos VH
    Fundam Appl Toxicol; 1985 Aug; 5(4):615-25. PubMed ID: 3840107
    [No Abstract]   [Full Text] [Related]  

  • 59. Safety assessment programs for U.S. regulatory agencies: a perspective of requirements and compliance.
    Bendele RA
    Toxicol Pathol; 1994; 22(2):95-104. PubMed ID: 7973375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thoughts on the proper use and interpretation of clinical pathology data in preclinical safety testing: a Canadian perspective.
    Mueller RW
    Toxicol Pathol; 1992; 20(3 Pt 2):526-7. PubMed ID: 1296285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.